嵌合式抗原受体 (CAR) T细胞疗法的神经毒性并发症
Frederick W Vonberg1,2, Imran Malik3, Maeve O'Reilly4,5
1National Hospital for Neurology and Neurosurgery, London, UK frederick.vonberg@nhs.net.
Journal of neurology, neurosurgery, and psychiatry
|April 4, 2025
概括
化学抗原受体 (CAR) T细胞治疗显示出有前途的结果,但可能导致严重的神经毒性. 随着CAR-T疗法的使用扩大,早期识别和多学科管理对于患者安全至关重要.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 神经学 神经学
背景情况:
- 化学抗原受体 (CAR) T细胞疗法已经改变了癌症治疗,在自身免疫性疾病中显示出潜力.
- 卡尔T细胞治疗与严重的神经毒性综合征有关,包括ICANS,运动障碍和认知障碍.
- 这些神经毒性并未得到充分了解,并可能导致患者显著的发病率和死亡率.
研究的目的:
- 突出了解和管理CAR T细胞疗法诱导的神经毒性的关键需求.
- 强调在处理这些不良事件时采用多学科方法的重要性.
主要方法:
- 关于CAR T细胞治疗和相关神经毒性的当前文献的综述.
- 报告的神经毒性综合征及其临床特征的分析.
- 讨论诊断和管理策略.
主要成果:
- 卡尔T细胞疗法与多种神经毒性综合征有关,其临床表现不同.
- 免疫效应细胞相关神经毒性综合征 (ICANS) 是一个主要问题.
- 其他新出现的神经毒性包括运动和神经认知治疗 - 新出现的不良事件和瘤炎症相关的神经毒性.
结论:
- 卡尔T细胞疗法诱导的神经毒性是一个重要的临床挑战,需要进一步研究.
- 有关神经病学家,血液病学家和瘤学家的协作方法对于有效的诊断和管理至关重要.
- 随着CAR T细胞治疗应用的扩大,积极的策略至关重要,以减轻神经毒性风险并改善患者的治疗结果.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.3K
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
475
相关概念视频
Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
154
Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
